StableBody Technologies


StableBody Technologies, LLC specializes in rational protein design and thermodynamic stabilization of antibody proteins to eliminate cold-chain logistics, reduce costs, and improve stability and efficacy. They leverage proprietary algorithms and computational biology to develop innovative solutions for biopharma, medical, and research industries, aiming to enhance health outcomes and streamline drug development and distribution.

Industries

biotechnology

Nr. of Employees

small (1-50)

StableBody Technologies


Products

Rational protein design platform (UI application)

A platform that applies proprietary thermodynamic and sequence-optimization algorithms through an intuitive interface to produce antibody sequences with improved thermal stability and affinity.


Services

Software service that accepts amino-acid sequence alignment data and applies thermodynamic optimization algorithms to generate candidate antibody sequences with improved thermal stability and binding properties.

Provision of diagnostic test panels and sample collection workflows including metabolic and amino-acid profiling with report generation and suggested personalized interventions.

Expertise Areas

  • Rational protein design
  • Thermodynamic protein stabilization
  • Computational biology and bioinformatics
  • Antibody engineering
  • Show More (4)

Key Technologies

  • Computational sequence optimization
  • Thermodynamic stabilization algorithms
  • Protein structural modeling
  • High-performance computing
  • Show More (5)

News & Updates

Regulatory environment can help support sponsors with the complex efforts involved in pediatric oncology drug development, as regulatory agencies and legislative acts have helped encourage incentivize or even.

Today, due to the very low proportion of platelets in the blood and to the complexity of this long and multi steps centrifuge-based manufacturing process, Blood Banks worldwide struggle to produce Platelets Concentrates with affordable pricing complying with high level regulatory mandatories.

Regulatory environment can help support sponsors with the complex efforts involved in pediatric oncology drug development, as regulatory agencies and legislative acts have helped encourage incentivize or even.

Today, due to the very low proportion of platelets in the blood and to the complexity of this long and multi steps centrifuge-based manufacturing process, Blood Banks worldwide struggle to produce Platelets Concentrates with affordable pricing complying with high level regulatory mandatories.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.